Related Experiment Video

Updated: Jun 2, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Immunomodulatory cytokines as therapeutic agents for melanoma

Courtney Nicholas1, Gregory B Lesinski

  • 1The Ohio State University, Department of Internal Medicine, Division of Medical Oncology, Columbus, OH 43210, USA.

Immunotherapy
|May 11, 2011
PubMed

Insights

Immunotherapy using cytokines shows promise for advanced melanoma, a rising cancer with limited treatments. Combining cytokine therapy with other approaches may improve patient outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Dermatology

Background:

  • Melanoma is an aggressive skin cancer with increasing global incidence.
  • Few effective treatments exist for metastatic melanoma, with chemotherapy often failing.
  • Cytokines like interferon-alfa (IFN-α) and interleukin-2 (IL-2) can enhance immune response against melanoma, sometimes yielding significant clinical benefits.

Purpose of the Study:

  • To discuss immunomodulatory agents for melanoma currently in clinical trials.
  • To explore challenges in cytokine therapy, including understanding pathways, dosing, and immunosuppression.
  • To consider the integration of targeted cytokine therapy and the potential for synergistic effects.

Main Methods:

  • Review of current immunomodulatory agents and their evaluation in clinical trials.
  • Discussion of challenges in cytokine therapy for advanced melanoma.
  • Analysis of evidence supporting combination therapies.

Main Results:

  • Several immunomodulatory agents are under investigation for melanoma treatment.
  • Significant challenges remain in optimizing cytokine therapy, including pathway elucidation and managing side effects.
  • Single-agent cytokine therapies have a low probability of success.

Conclusions:

  • Cytokine immunotherapy holds potential for melanoma treatment, but challenges need addressing.
  • Synergistic effects are observed between cytokine immunotherapy and other therapeutic strategies.
  • Further research is crucial to optimize cytokine therapy's role in melanoma management.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...